tirzepatide and osteoporosis Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Frontiers | The gut–bone axis

Audio Commentary by Dr Katrina Pears ME/CFS Research Published 13 20 February 2023 Its been a comparatively quiet week for ME/CFS research, with four new ME/CFS studies but seventeen new Long Covid studies

Some oral studies exist for similar ingredients

Most treatments take just 30-45 minutes, with many patients experiencing relief during the session

H 2 O 2, hydrogen peroxide

FDA (June 2021), UK MHRA (September 2021), Health Canada (November 2021) and the European Medicines Agency (January 2022) has raised hopes for people living with obesity and made Novo Nordisk continental Europes second most-valuable public company (after LVMH)